Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4072-4079
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4072
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4072
Figure 3 Cumulative rates of sustained hepatitis B e antigen (HBeAg) seroconversion during one year of treatment with lamivudine (dashed line) and after switching to adefovir (continuous line).
Only patients with positive HBeAg values at baseline were included in the analysis. Cumulative rates after one-year treatment of lamivudine and adefovir were 13% and 15%, respectively. LMV: lamivudine; ADV: adefovir dipivoxil; HBeAg: hepatitis B e antigen.
- Citation: Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4072.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4072